Effects of Alirocumab and Evolocumab on the outcomes and lipid profile of diabetic patients: Meta-analysis of randomized controlled trials.
Anno:
2023
Objective: To evaluate the specific effects of alirocumab and evolocumab on major cardiovascular events (MACE) and lipid profile in patients with diabetes. Methods: We conducted a systematic review of literature according to the PRISMA statement. A total of 8 randomized control trials (RCTs) enrolling 20651 patients with diabetes were included….